Working… Menu

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). (BABH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03227263
Recruitment Status : Recruiting
First Posted : July 24, 2017
Last Update Posted : July 10, 2018
Information provided by (Responsible Party):
Hospices Civils de Lyon

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020